- Home
- AMLX
as 12-20-2024 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 481.9M | IPO Year: | 2022 |
| Target Price: | $7.60 | AVG Volume (30 days): | 687.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $19.95 | Next Earning Date: | 11-07-2024 |
| Revenue: | $196,485,000 | Revenue Growth: | -33.22% |
| Revenue Growth (this year): | -76.45% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | AMLX | Chief Medical Officer | Dec 2 '24 | Sell | $5.54 | 5,421 | $30,007.40 | 138,380 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Sep 30 '24 | Sell | $3.20 | 18,589 | $59,414.16 | 3,220,569 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Sep 30 '24 | Sell | $3.20 | 8,709 | $27,840.06 | 142,768 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Sep 30 '24 | Sell | $3.20 | 18,589 | $59,429.03 | 3,120,569 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Sep 30 '24 | Sell | $3.20 | 11,442 | $36,559.48 | 138,380 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
TipRanks
16 days ago
Amylyx announces design of LUCIDITY clinical trial
Business Wire
17 days ago
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Business Wire
24 days ago
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
MT Newswires
a month ago
Baird Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Adjusts Price Target to $11 From $3
Simply Wall St.
a month ago
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)
GuruFocus.com
a month ago
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Thomson Reuters StreetEvents
a month ago
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call
Business Wire
a month ago
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.